Annotation: Oral deferiprone - Controversies on its efficacy and safety

Indian Journal of Pediatrics

Volumn 65, Issue 6, 1998, Pages 825-828

  Choudhry, V P ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IRON; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

AGRANULOCYTOSIS; BETA THALASSEMIA; BONE MARROW TOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; HUMAN; INDIA; IRON CHELATION; IRON OVERLOAD; ORAL DRUG ADMINISTRATION; CHILD; DEVELOPING COUNTRY; GENETICS; HETEROZYGOTE DETECTION; REVIEW; TREATMENT OUTCOME;

BETA-THALASSEMIA; CHILD; CLINICAL TRIALS; DEVELOPING COUNTRIES; HETEROZYGOTE DETECTION; HUMANS; INDIA; IRON CHELATING AGENTS; PYRIDONES; TREATMENT OUTCOME;

EID: 0032417990     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02831341     Document Type: Conference Paper

References (18)

1. Choudhry VP, Desai N, Pati HP and Nanu A. Current management of hemozygous beta thalassemia. Ind Pediatr 1991; 28 : 1221-1229.
2. Andersoo WF, Hiller MC (eds). Development of Iron Chelators for Clinical Use. National Institute of Health. Bethesda, U.S.A. 1975; 1-277.
3. Martell AE, Anderson WF, Badman DG (eds). Development of Iron Chelators for Clinical Use. Amsterdam : Elsevier Scientific Publishers, 1980; 1-311.
4. Oral chelation in the treatment of thalassemia and other diseases. Drugs Today 1992; 28 (suppl A) : 1-187.
5. Goudsmit R, Kersten MJ. Long term treatment of transfusion hemosiderosis with the oral iron chela tor L1. Drugs Today 1992; 28 (suppl 1) : 133-135.
6. Dersten MJ, Lange RV, Smeets MEP et al. Long term treatment of transfusional iron overload with oral iron chelator 1-2 dimethyl, 3 hydroxypyrid 4-one (Deferiprone). International Congress on oral chelation in the treatment of thalassemia and other diseases. 1995; p 16.
7. Agarwal MB, Gupta SS, Viswanathan C et al. Long term assessment of efficacy and safety of L1, an oral iron chelator in transfusion dependent thalassemia : Indian trial. Br J Haematol 1992; 82 : 460-466.
8. Choudhry VP and Pati HP. Oral iron chelator deferiprone. In : Suraj Gupta (ed). Recent Advances in Pediatrics. Jaypee Brothers 1996; Vol 6 : pp 229-240.
9. Choudhry VP, Malviya AN, Pati HP, Saxena A and Subramaniyam V. To evalaute the efficacy and safety of oral iron chelator 1-2 Demethyl 3 Hydroxypyrid-4-one chelator (L1) compound in mutiple transfused thalassemic patients (Report submitted to Cipla) 1995.
10. Mazza P, Amurri B, Lazzari G et al. Oral iron chelating therapy. A single centre interim report on deferiprone (L) in thalassemia. Hematologica 1998; 83 : 496-501.
11. Olivieri NF, Brittenham GM, Matsui D et al. Iron chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995; 332 : 918-22.
12. Olivieri NF. Randomized trial of deferiprone (L1) and deferoxamine (DFO) in thalassemia major. Blood 1996; 88 : 651a abstract.
13. Hoffbrand AV, Al Refaie F, Davis B et al. Long term trial of deferiprone in 51 transfusion dependent iron overloaded patients. Blood 1998; 91 : 295-300.
14. Olivieri NF, Brittenham GM, McLaren CE et al. Long term safety and effectiveness of iron chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339 : 417-23.
15. Agarwal MB, Gupta SS, Vishwanathan C et al. Long term efficacy and toxicity of L1 oral iron chelation in transfusion dependent thalassemics over the last three years (1989-92) (Abstract) 5th International Conference on Thalassemia and Haemoglobinopathies held at Cyprus 1993; p 192.
16. Hoffbrand AV. Oral iron chelation. Seminar Hematol 1996; 33 : 1-8.
17. Citrin OD and Koren D. Oral iron chelation with deferiprone. Ped Clin N Am 1997; 44 : 235-247.
18. 1) associated neutropenia in beta thalassemia major. An Indian experience. Eurp J Hematol (Submitted for publication).